Notice: This company has been marked as potentially delisted and may not be actively trading. Apricus Biosciences (APRI) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends APRI vs. FGEN, VRCA, IXHL, IRD, MDCX, RAPT, OKUR, RNXT, CPIX, and PMNShould you be buying Apricus Biosciences stock or one of its competitors? The main competitors of Apricus Biosciences include FibroGen (FGEN), Verrica Pharmaceuticals (VRCA), Incannex Healthcare (IXHL), Opus Genetics (IRD), Medicus Pharma (MDCX), RAPT Therapeutics (RAPT), OnKure Therapeutics (OKUR), RenovoRx (RNXT), Cumberland Pharmaceuticals (CPIX), and ProMIS Neurosciences (PMN). These companies are all part of the "medical" sector. Apricus Biosciences vs. FibroGen Verrica Pharmaceuticals Incannex Healthcare Opus Genetics Medicus Pharma RAPT Therapeutics OnKure Therapeutics RenovoRx Cumberland Pharmaceuticals ProMIS Neurosciences Apricus Biosciences (NASDAQ:APRI) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, community ranking, profitability, media sentiment and institutional ownership. Is APRI or FGEN more profitable? Apricus Biosciences has a net margin of 0.00% compared to FibroGen's net margin of -67.66%. FibroGen's return on equity of 0.00% beat Apricus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Apricus BiosciencesN/A -216.45% -153.13% FibroGen -67.66%N/A -36.17% Does the MarketBeat Community prefer APRI or FGEN? FibroGen received 114 more outperform votes than Apricus Biosciences when rated by MarketBeat users. However, 69.91% of users gave Apricus Biosciences an outperform vote while only 60.35% of users gave FibroGen an outperform vote. CompanyUnderperformOutperformApricus BiosciencesOutperform Votes23069.91% Underperform Votes9930.09% FibroGenOutperform Votes34460.35% Underperform Votes22639.65% Which has more volatility & risk, APRI or FGEN? Apricus Biosciences has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Does the media favor APRI or FGEN? In the previous week, FibroGen had 15 more articles in the media than Apricus Biosciences. MarketBeat recorded 15 mentions for FibroGen and 0 mentions for Apricus Biosciences. FibroGen's average media sentiment score of 0.67 beat Apricus Biosciences' score of 0.00 indicating that FibroGen is being referred to more favorably in the news media. Company Overall Sentiment Apricus Biosciences Neutral FibroGen Positive Do analysts recommend APRI or FGEN? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apricus Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00FibroGen 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, APRI or FGEN? Apricus Biosciences has higher earnings, but lower revenue than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Apricus Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApricus Biosciences$5.76M1.30$320K-$0.99-0.27FibroGen$180.02M0.22-$284.23M-$1.23-0.33 Do insiders and institutionals hold more shares of APRI or FGEN? 19.9% of Apricus Biosciences shares are owned by institutional investors. Comparatively, 72.7% of FibroGen shares are owned by institutional investors. 2.3% of Apricus Biosciences shares are owned by company insiders. Comparatively, 2.0% of FibroGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryFibroGen beats Apricus Biosciences on 9 of the 17 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Apricus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APRI vs. The Competition Export to ExcelMetricApricus BiosciencesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.51M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E Ratio-0.2710.5990.0517.18Price / Sales1.30196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book0.925.094.784.78Net Income$320,000.00$151.83M$120.31M$225.60M Apricus Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APRIApricus BiosciencesN/A$0.27-8.0%N/A-81.9%$7.51M$5.76M-0.27N/AGap UpFGENFibroGen2.437 of 5 stars$0.33-1.9%N/A-42.4%$32.92M$180.02M-0.28486Analyst UpgradeAnalyst RevisionNews CoverageVRCAVerrica Pharmaceuticals4.6589 of 5 stars$0.72-5.4%$9.50+1,220.4%-89.2%$32.81M$5.12M-0.4040Analyst ForecastNews CoverageIXHLIncannex HealthcareN/A$1.83-1.6%N/A-55.1%$32.29M$86,000.00-1.343IRDOpus Genetics2.7234 of 5 stars$1.02flat$8.00+684.3%N/A$32.20M$8.38M-0.92N/ANews CoverageGap UpMDCXMedicus PharmaN/A$2.95+7.3%N/AN/A$32.00MN/A0.00N/AAnalyst ForecastRAPTRAPT Therapeutics4.5182 of 5 stars$0.91-0.3%$9.50+946.9%-96.3%$31.72M$1.53M-0.3380OKUROnKure Therapeutics3.4509 of 5 stars$9.25-6.2%$36.00+289.2%N/A$30.90MN/A-0.81N/AHigh Trading VolumeRNXTRenovoRx1.2233 of 5 stars$1.27-0.8%$6.50+411.8%+47.1%$30.48MN/A-2.256Gap UpCPIXCumberland Pharmaceuticals0.3276 of 5 stars$2.15-9.7%N/A+33.5%$30.19M$36.79M-2.8380Analyst ForecastNews CoverageGap DownPMNProMIS Neurosciences1.0591 of 5 stars$0.91-2.7%N/A-20.0%$29.58M$10,000.00-9.306Positive News Related Companies and Tools Related Companies FGEN Competitors VRCA Competitors IXHL Competitors IRD Competitors MDCX Competitors RAPT Competitors OKUR Competitors RNXT Competitors CPIX Competitors PMN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APRI) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apricus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apricus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
